Latest Insider Transactions at Apellis Pharmaceuticals, Inc. (APLS)
This section provides a real-time view of insider transactions for Apellis Pharmaceuticals, Inc. (APLS). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Apellis Pharmaceuticals, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Apellis Pharmaceuticals, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 23
2023
|
Karen Lewis Chief People Officer |
SELL
Open market or private sale
|
Direct |
2,955
-7.27%
|
$150,705
$51.58 P/Share
|
|
Jan 20
2023
|
Adam J. Townsend Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,912
-2.72%
|
$99,424
$52.05 P/Share
|
|
Jan 20
2023
|
David O. Watson General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
2,034
-1.2%
|
$105,768
$52.05 P/Share
|
|
Jan 20
2023
|
Karen Lewis Chief People Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,411
-3.35%
|
$73,372
$52.05 P/Share
|
|
Jan 20
2023
|
Nur Nicholson Chief Technical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,034
-3.57%
|
$105,768
$52.05 P/Share
|
|
Jan 20
2023
|
Lukas Scheibler Chief Research Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,015
-3.16%
|
$104,780
$52.05 P/Share
|
|
Jan 20
2023
|
Timothy Eugene Sullivan Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,379
-1.87%
|
$123,708
$52.05 P/Share
|
|
Jan 20
2023
|
Jeffrey Eisele Chief Development Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,033
-3.75%
|
$105,716
$52.05 P/Share
|
|
Jan 20
2023
|
Cedric Francois Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
9,453
-0.9%
|
$491,556
$52.05 P/Share
|
|
Jan 20
2023
|
Mark Jeffrey De Long Chief Business & Strat Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,149
-2.36%
|
$59,748
$52.05 P/Share
|
|
Jan 20
2023
|
Pascal Deschatelets Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,326
-0.23%
|
$120,952
$52.05 P/Share
|
|
Jan 20
2023
|
Victoria L. Brown Program Team Lead |
SELL
Payment of exercise price or tax liability
|
Direct |
1,412
-5.66%
|
$73,424
$52.05 P/Share
|
|
Jan 20
2023
|
James George Chopas VP/Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
919
-3.27%
|
$47,788
$52.05 P/Share
|
|
Jan 17
2023
|
Alec Machiels Director |
SELL
Open market or private sale
|
Direct |
1,250
-0.46%
|
$65,000
$52.42 P/Share
|
|
Jan 17
2023
|
Alec Machiels Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,250
+0.46%
|
$2,500
$2.67 P/Share
|
|
Jan 12
2023
|
James George Chopas VP/Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,621
+25.52%
|
-
|
|
Jan 12
2023
|
Timothy Eugene Sullivan Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
27,488
+17.78%
|
-
|
|
Jan 12
2023
|
Nur Nicholson Chief Technical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
22,580
+28.36%
|
-
|
|
Jan 12
2023
|
Lukas Scheibler Chief Research Officer |
BUY
Grant, award, or other acquisition
|
Direct |
22,580
+26.17%
|
-
|
|
Jan 12
2023
|
Adam J. Townsend Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
27,488
+28.08%
|
-
|
|
Jan 12
2023
|
David O. Watson General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
53,455
+14.76%
|
-
|
|
Jan 12
2023
|
Pascal Deschatelets Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
19,634
+1.92%
|
-
|
|
Jan 12
2023
|
Jeffrey Eisele Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
22,580
+29.4%
|
-
|
|
Jan 12
2023
|
Cedric Francois Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
83,447
+7.37%
|
-
|
|
Jan 12
2023
|
Karen Lewis Chief People Officer |
BUY
Grant, award, or other acquisition
|
Direct |
19,634
+31.82%
|
-
|
|
Jan 12
2023
|
Mark Jeffrey De Long Chief Business & Strat Officer |
BUY
Grant, award, or other acquisition
|
Direct |
19,634
+28.74%
|
-
|
|
Jan 09
2023
|
Pascal Deschatelets Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
12,000
-1.21%
|
$552,000
$46.08 P/Share
|
|
Jan 09
2023
|
Pascal Deschatelets Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
18,500
+1.82%
|
$37,000
$2.67 P/Share
|
|
Jan 05
2023
|
Federico Grossi Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,500
-2.57%
|
$120,000
$48.79 P/Share
|
|
Jan 03
2023
|
Adam J. Townsend Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
5,000
-10.44%
|
$250,000
$50.7 P/Share
|
|
Jan 03
2023
|
Adam J. Townsend Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+9.45%
|
$75,000
$15.09 P/Share
|
|
Jan 03
2023
|
Caroline Baumal Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
35,549
+49.91%
|
-
|
|
Jan 03
2023
|
A. Sinclair Dunlop Director |
SELL
Open market or private sale
|
Direct |
500
-0.38%
|
$25,000
$50.7 P/Share
|
|
Jan 01
2023
|
Paul R. Fonteyne Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,867
+22.8%
|
-
|
|
Jan 01
2023
|
Gerald Chan Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,867
+32.32%
|
-
|
|
Jan 01
2023
|
Stephanie Monaghan O'Brien Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,867
+32.32%
|
-
|
|
Jan 01
2023
|
A. Sinclair Dunlop Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,867
+2.82%
|
-
|
|
Jan 01
2023
|
Alec Machiels Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,867
+1.42%
|
-
|
|
Dec 29
2022
|
Pascal Deschatelets Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,000
+0.71%
|
$21,000
$3.67 P/Share
|
|
Dec 22
2022
|
Jeffrey Eisele Chief Development Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
89
-0.28%
|
$4,539
$51.68 P/Share
|
|
Dec 19
2022
|
Cedric Francois Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
28,200
-1.42%
|
$1,466,400
$52.02 P/Share
|
|
Dec 19
2022
|
Cedric Francois Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
49,888
+1.66%
|
$349,216
$7.13 P/Share
|
|
Dec 15
2022
|
Alec Machiels Director |
SELL
Open market or private sale
|
Direct |
1,250
-0.47%
|
$65,000
$52.35 P/Share
|
|
Dec 15
2022
|
Alec Machiels Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,250
+0.47%
|
$2,500
$2.67 P/Share
|
|
Dec 08
2022
|
Pascal Deschatelets Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
12,000
-1.22%
|
$564,000
$47.5 P/Share
|
|
Dec 08
2022
|
Pascal Deschatelets Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
18,500
+1.85%
|
$37,000
$2.67 P/Share
|
|
Dec 05
2022
|
Adam J. Townsend Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
5,000
-10.44%
|
$250,000
$50.38 P/Share
|
|
Dec 05
2022
|
Adam J. Townsend Chief Commercial Officer |
SELL
Exercise of conversion of derivative security
|
Direct |
5,000
-9.45%
|
$75,000
$15.09 P/Share
|
|
Dec 01
2022
|
Federico Grossi Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,500
-2.5%
|
$122,500
$49.93 P/Share
|
|
Dec 01
2022
|
A. Sinclair Dunlop Director |
SELL
Open market or private sale
|
Direct |
500
-0.38%
|
$24,500
$49.93 P/Share
|